Every 8-K that Treace Medical Concepts, Inc. (TMCI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TMCI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMCI filings page.
Treace Medical Concepts, Inc. reported second quarter 2026 revenue of $45.4 million, a 4% decline from $47.4 million a year earlier, with gross margin of 78.5%. Net loss was $15.9 million, or $0.24 per share, slightly better than $17.4 million, or $0.28 per share, in 2025. Adjusted EBITDA was a loss of $3.5 million, essentially flat year over year.
Total operating expenses fell 8% to $50.6 million, helping reduce year‑to‑date cash usage by 57% or $3.6 million. Cash, cash equivalents and marketable securities were $45.6 million as of June 30, 2026, and an existing credit facility provides up to $115 million of additional liquidity, subject to conditions. The company raised its 2026 revenue outlook to $204–$212 million, representing a 4% to 0% decline versus 2025, and now expects an Adjusted EBITDA loss of $3.0–$5.0 million, compared with a $3.9 million loss in 2025. Management highlighted growing adoption of its expanded bunion portfolio and new product launches including the SuperBite Compression Screw and HyperPlate XM systems.
Treace Medical Concepts, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class II directors Lance A. Berry, Elizabeth S. Hanna, and Jane E. Kiernan to three-year terms expiring at the 2029 annual meeting.
Stockholders also approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers, and ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Treace Medical Concepts reported first quarter 2026 revenue of $47.2 million, a 10% decline from $52.6 million in the same period of 2025. Gross profit was $37.4 million with gross margin steady at 79.3%. Net loss widened to $18.0 million, or $0.28 per share, and Adjusted EBITDA was a loss of $5.5 million.
Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, and the company also has access to an existing credit facility providing an additional $115 million of liquidity. Management reaffirmed full-year 2026 revenue guidance of $202–$212 million and expects an Adjusted EBITDA loss of $4–$6 million, alongside about a 50% reduction in cash usage versus 2025.
Treace Medical Concepts, Inc. announced preliminary first quarter 2026 results and a leadership change. For the three months ended March 31, 2026, preliminary revenue is expected to be in the range of $47.0 million to $47.2 million. Preliminary cash, cash equivalents and marketable securities are expected to total about $51.9 million as of March 31, 2026, up from $48.4 million as of December 31, 2025 and a smaller increase in the first quarter of 2025.
The company updated its full-year 2026 revenue guidance to $202 million to $212 million, slightly raising the low end of the prior outlook to reflect continued case volume growth and headwinds from product and price mix in its expanded bunion portfolio. Treace also disclosed that Chief Commercial Officer Gaetano M. Guglielmino will depart as of April 8, 2026. His responsibilities will be absorbed by existing staff, with the Senior Vice President, Sales reporting directly to the Chief Executive Officer. Guglielmino will serve as an independent consultant through January 31, 2027 under a paid consulting agreement that includes a monthly fee, COBRA premiums, a pro-rated 2026 bonus, apartment rent coverage until lease assignment, and continued vesting of prior equity awards.
Treace Medical Concepts reported 2025 revenue of $212.7 million, up 2% year over year, with fourth quarter revenue of $62.5 million, down 9% as sales shifted toward lower priced bunion kits. Full-year net loss widened slightly to $59.0 million, or $(0.93) per share, while the adjusted EBITDA loss improved to $(3.9) million from $(11.0) million.
Cash, cash equivalents and marketable securities were $48.4 million at December 31, 2025, and cash usage fell 46% to $27.3 million. The company added 202 net new active surgeons and ended 2025 with 3,337 active surgeons, about 33% of its estimated 10,000 U.S. bunion surgeons. Treace now holds 135 granted patents and 199 pending applications.
For 2026, Treace guided to revenue of $200 million to $212 million, implying 6% decline to flat versus 2025, and an adjusted EBITDA loss of $4.0 million to $6.0 million. Management expects roughly 50% lower cash usage in 2026, supported by a new credit facility that provides $115 million of additional liquidity subject to conditions.
Treace Medical Concepts reported that it has released certain preliminary unaudited financial results for the quarter and year ended December 31, 2025. These results are shared through a press release furnished as an exhibit and are not treated as formally filed financial statements. The company also posted an updated investor presentation on its investor relations website.
Treace plans to use this presentation in meetings with analysts and investors, including at the J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. A live webcast of this event, along with an archived recording and the presentation, will be available in the Investors section of the company’s website.
Treace Medical Concepts entered into new 60‑month credit facilities consisting of a term loan agreement with SLR Investment Corp. providing up to $125 million across four tranches and a revolving loan agreement with SLR Healthcare ABL providing a $30 million revolver, with potential increases to a total commitment of $50 million. The company drew $60 million at closing under the first term loan tranche. The term loan bears interest at 1‑Month SOFR plus 5.05%, while the revolver bears interest at 3‑Month SOFR plus 4.00%, with additional fees tied to servicing, unused capacity and early repayment.
The loans are secured by substantially all company assets and include a minimum liquidity requirement under which cash and cash equivalents in controlled accounts must exceed 60% of term loans outstanding, with revenue covenants applying if that test is not met. Treace used proceeds from the new term loan to repay and terminate its prior MidCap term and revolving credit agreements, paying $2.3 million in prepayment and exit fees. The new covenants limit the company’s ability to pay cash dividends unless financial conditions in the loan agreements are satisfied. The board also appointed long‑time director John K. Bakewell as lead independent director.
Treace Medical Concepts (TMCI) furnished its Q3 2025 results via a press release attached as Exhibit 99.1. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company also announced a board change. Richard W. Mott retired from the Board on November 3, 2025, for personal reasons and not due to any disagreement. On November 5, 2025, the Board reduced its size from eight to seven members; there are currently no vacancies.